Immunoassay Market by Product, Technology, Specimen, Application, End User & Region Global Forecast to 2031
The global immunoassay market is estimated to be valued at USD 31.65 billion in 2026 and is projected to reach USD 44.49 billion by 2031, registering a CAGR of 7.0% during the forecast period. Mar... もっと見る
英語原文をAIを使って翻訳しています。
図表リストFIGURE 1 IMMUNOASSAY MARKET SEGMENTATION & REGIONAL SCOPE 39.FIGURE 2 IMMUNOASSAY MARKET: YEARS CONSIDERED 41. FIGURE 3 KEY INSIGHTS & MARKET HIGHLIGHTS 43. FIGURE 4 GLOBAL IMMUNOASSAY MARKET, 2024–2031 44. FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN IMMUNOASSAY MARKET, 2024–2026 44. FIGURE 6 DISRUPTIVE TRENDS IMPACTING GROWTH OF IMMUNOASSAY MARKET 45. FIGURE 7 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS IN. IMMUNOASSAY MARKET, 2025 46. FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 47. FIGURE 9 HIGH PREVALENCE OF CHRONIC AND INFECTIOUS DISEASES TO DRIVE MARKET 48. FIGURE 10 REAGENTS & KITS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 49. FIGURE 11 CLIA SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 49. FIGURE 12 BLOOD SAMPLES SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 50. FIGURE 13 INFECTIOUS DISEASES SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 50. FIGURE 14 HOSPITALS & CLINICS SEGMENT TO COMMAND LARGEST. SHARE DURING FORECAST PERIOD 51. FIGURE 15 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 51. FIGURE 16 IMMUNOASSAY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,. AND CHALLENGES 53. FIGURE 17 IMMUNOASSAY MARKET: PORTER’S FIVE FORCES ANALYSIS 71. FIGURE 18 IMMUNOASSAY MARKET: SUPPLY CHAIN ANALYSIS 76. FIGURE 19 IMMUNOASSAY MARKET: VALUE CHAIN ANALYSIS 77. FIGURE 20 IMMUNOASSAY MARKET: ECOSYSTEM ANALYSIS 78. FIGURE 21 IMMUNOASSAY MARKET: TRENDS/DISRUPTIONS IMPACTING. CUSTOMERS’ BUSINESSES 85. FIGURE 22 NUMBER OF DEALS & FUNDING ACTIVITIES IN IMMUNOASSAY MARKET 86. FIGURE 23 TOP 10 PATENT OWNERS/APPLICANTS IN IMMUNOASSAY MARKET,. JANUARY 2015–DECEMBER 2024 93. FIGURE 24 MARKET POTENTIAL OF AI IN IMMUNOASSAY MARKET 96. FIGURE 25 US: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 99. FIGURE 26 CANADA: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 100. FIGURE 27 JAPAN: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 102. FIGURE 28 INDIA: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 104. FIGURE 29 MEXICO: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 106. FIGURE 30 BRAZIL: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 108. FIGURE 31 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER 113. FIGURE 32 KEY BUYING CRITERIA, BY END USER 114. FIGURE 33 NORTH AMERICA: IMMUNOASSAY MARKET SNAPSHOT 248. FIGURE 34 ASIA PACIFIC: IMMUNOASSAY MARKET SNAPSHOT 302. FIGURE 35 REVENUE ANALYSIS OF KEY PLAYERS IN IMMUNOASSAY MARKET,. 2023–2025 (USD MILLION) 364. FIGURE 36 IMMUNOASSAY MARKET SHARE ANALYSIS, 2025 (GLOBAL) 365. FIGURE 37 IMMUNOASSAY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 367. FIGURE 38 IMMUNOASSAY MARKET: COMPANY FOOTPRINT 368. FIGURE 39 IMMUNOASSAY MARKET: COMPANY EVALUATION MATRIX. (STARTUPS/SMES), 2025 373. FIGURE 40 EV/EBITDA OF KEY VENDORS 376. FIGURE 41 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA. OF KEY VENDORS 376. FIGURE 42 IMMUNOASSAY MARKET: BRAND/PRODUCT COMPARISON 377. FIGURE 43 ABBOTT: COMPANY SNAPSHOT (2025) 381. FIGURE 44 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2025) 387. FIGURE 45 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2025) 393. FIGURE 46 DANAHER CORPORATION: COMPANY SNAPSHOT (2025) 398. FIGURE 47 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025) 405. FIGURE 48 REVVITY INC.: COMPANY SNAPSHOT (2025) 410. FIGURE 49 WATERS CORPORATION: COMPANY SNAPSHOT (2025) 413. FIGURE 50 DIASORIN S.P.A.: COMPANY SNAPSHOT (2025) 416. FIGURE 51 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2025) 421. FIGURE 52 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2025) 425. FIGURE 53 BIOMÉRIEUX: COMPANY SNAPSHOT (2025) 430. FIGURE 54 QIAGEN: COMPANY SNAPSHOT (2025) 434. FIGURE 55 SYSMEX CORPORATION: COMPANY SNAPSHOT (2025) 437. FIGURE 56 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025) 442. FIGURE 57 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.:. COMPANY SNAPSHOT (2025) 444. FIGURE 58 IMMUNOASSAY MARKET: RESEARCH DESIGN 459. FIGURE 59 IMMUNOASSAY MARKET: KEY DATA FROM SECONDARY SOURCES 461. FIGURE 60 IMMUNOASSAY MARKET: KEY PRIMARY SOURCES 461. FIGURE 61 IMMUNOASSAY MARKET: KEY INSIGHTS FROM INDUSTRY EXPERTS 464. FIGURE 62 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND. DEMAND-SIDE PARTICIPANTS 464. FIGURE 63 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,. DESIGNATION, AND REGION 465. FIGURE 64 IMMUNOASSAY MARKET: COMPANY REVENUE ESTIMATION. (REVENUE SHARE ANALYSIS) 466. FIGURE 65 IMMUNOASSAY MARKET: CAGR PROJECTIONS (SUPPLY-SIDE ANALYSIS) 467. FIGURE 66 IMMUNOASSAY MARKET: TOP-DOWN APPROACH 468. FIGURE 67 IMMUNOASSAY MARKET: DATA TRIANGULATION METHODOLOGY 469. TABLE 1 IMMUNOASSAY MARKET: INCLUSIONS & EXCLUSIONS 40. TABLE 2 INCREASING INCIDENCE OF CANCER, BY REGION, 2024 VS. 2040 (MILLION) 55. TABLE 3 NUMBER OF NEW CANCER CASES, BY CANCER TYPE, 2024 55. TABLE 4 DETECTION TIME OF DRUG OR DRUG CLASS IN URINE TESTING 56. TABLE 5 NEW TESTS LAUNCHED BY KEY PLAYERS, 2023–2026 63. TABLE 6 LAB-ON-CHIP IMMUNOASSAYS/DEVICES/SYSTEMS OFFERED BY KEY PLAYERS 63. TABLE 7 IMMUNOASSAY MARKET: PORTER’S FIVE FORCES 71. TABLE 8 GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2023–2030 73. TABLE 9 NORTH AMERICA: MACROECONOMIC INDICATORS 74. TABLE 10 EUROPE: MACROECONOMIC INDICATORS 74. TABLE 11 ASIA PACIFIC: MACROECONOMIC INDICATORS 75. TABLE 12 LATIN AMERICA: MACROECONOMIC INDICATORS 75. TABLE 13 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS 75. TABLE 14 IMMUNOASSAY MARKET: ROLE OF COMPANIES IN ECOSYSTEM 79. TABLE 15 AVERAGE SELLING PRICE TREND OF IMMUNOASSAY PRODUCTS,. BY KEY PLAYER, 2024–2026 (USD) 80. TABLE 16 AVERAGE SELLING PRICE TREND OF CLINICAL IMMUNOASSAY ANALYZERS,. BY REGION, 2024–2026 (USD) 81. TABLE 17 AVERAGE SELLING PRICE TREND OF IMMUNOASSAY PRODUCTS, BY TYPE,. 2024–2026 (USD) 82. TABLE 18 IMPORT DATA FOR HS CODE 382200-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION) 83. TABLE 19 EXPORT DATA FOR HS CODE 382200-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION) 84. TABLE 20 IMMUNOASSAY MARKET: KEY CONFERENCES & EVENTS, 2026–2027 84. TABLE 21 US-ADJUSTED RECIPROCAL TARIFF RATES 87. TABLE 22 KEY PATENTS IN IMMUNOASSAY, 2023–2026 94. TABLE 23 KEY COMPANIES IMPLEMENTING AI IN IMMUNOASSAY MARKET 97. TABLE 24 US: CLASSIFICATION AND RISK LEVEL OF IMMUNOASSAY PRODUCTS 98. TABLE 25 EUROPE: CLASSIFICATION AND RISK LEVEL OF IN VITRO DIAGNOSTIC DEVICES 101. TABLE 26 RUSSIA: CLASSIFICATION AND RISK LEVEL OF IN VITRO DIAGNOSTIC DEVICES 101. TABLE 27 JAPAN: CLASSIFICATION OF IN VITRO DIAGNOSTIC REAGENTS 102. TABLE 28 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 103. TABLE 29 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 103. TABLE 30 INDONESIA: REGISTRATION PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 104. TABLE 31 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 105. TABLE 32 SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 106. TABLE 33 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 107. TABLE 34 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,. AND OTHER ORGANIZATIONS 108. TABLE 35 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,. AND OTHER ORGANIZATIONS 109. TABLE 36 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,. AND OTHER ORGANIZATIONS 109. TABLE 37 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,. AND OTHER ORGANIZATIONS 109. TABLE 38 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES,. AND OTHER ORGANIZATIONS 110. TABLE 39 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER (%) 113. TABLE 40 KEY BUYING CRITERIA, BY END USER 114. TABLE 41 ADOPTION BARRIERS & INTERNAL CHALLENGES 115. TABLE 42 IMMUNOASSAY MARKET: UNMET NEEDS IN VARIOUS END-USE INDUSTRIES 116. TABLE 43 IMMUNOASSAY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 119. TABLE 44 KEY REAGENTS & KITS AVAILABLE IN MARKET 120. TABLE 45 IMMUNOASSAY REAGENTS & KITS MARKET, BY REGION,. 2024–2031 (USD MILLION) 121. TABLE 46 IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2024–2031 (USD MILLION) 121. TABLE 47 NORTH AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET,. BY COUNTRY, 2024–2031 (USD MILLION) 122. TABLE 48 EUROPE: IMMUNOASSAY REAGENTS & KITS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 122. TABLE 49 ASIA PACIFIC: IMMUNOASSAY REAGENTS & KITS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 123. TABLE 50 LATIN AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 123. TABLE 51 ELISA REAGENTS & KITS MARKET, BY REGION, 2024–2031 (USD MILLION) 125. TABLE 52 NORTH AMERICA: ELISA REAGENTS & KITS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 125. TABLE 53 EUROPE: ELISA REAGENTS & KITS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 126. TABLE 54 ASIA PACIFIC: ELISA REAGENTS & KITS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 126. TABLE 55 LATIN AMERICA: ELISA REAGENTS & KITS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 127. TABLE 56 RAPID TEST REAGENTS & KITS MARKET, BY REGION, 2024–2031 (USD MILLION) 128. TABLE 57 NORTH AMERICA: RAPID TEST REAGENTS & KITS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 128. TABLE 58 EUROPE: RAPID TEST REAGENTS & KITS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 129. TABLE 59 ASIA PACIFIC: RAPID TEST REAGENTS & KITS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 129. TABLE 60 LATIN AMERICA: RAPID TEST REAGENTS & KITS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 130. TABLE 61 CLIA REAGENTS & KITS MARKET, BY REGION, 2024–2031 (USD MILLION) 131. TABLE 62 NORTH AMERICA: CLIA REAGENTS & KITS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 131. TABLE 63 EUROPE: CLIA REAGENTS & KITS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 132. TABLE 64 ASIA PACIFIC: CLIA REAGENTS & KITS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 132. TABLE 65 LATIN AMERICA: CLIA REAGENTS & KITS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 133. TABLE 66 IFA REAGENTS & KITS MARKET, BY REGION, 2024–2031 (USD MILLION) 133. TABLE 67 NORTH AMERICA: IFA REAGENTS & KITS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 134. TABLE 68 EUROPE: IFA REAGENTS & KITS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 134. TABLE 69 ASIA PACIFIC: IFA REAGENTS & KITS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 135. TABLE 70 LATIN AMERICA: IFA REAGENTS & KITS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 135. TABLE 71 WESTERN BLOT REAGENTS & KITS MARKET, BY REGION,. 2024–2031 (USD MILLION) 136. TABLE 72 NORTH AMERICA: WESTERN BLOT REAGENTS & KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 137. TABLE 73 EUROPE: WESTERN BLOT REAGENTS & KITS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 137. TABLE 74 ASIA PACIFIC: WESTERN BLOT REAGENTS & KITS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 138. TABLE 75 LATIN AMERICA: WESTERN BLOT REAGENTS & KITS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 138. TABLE 76 OTHER REAGENTS & KITS MARKET, BY REGION, 2024–2031 (USD MILLION) 139. TABLE 77 NORTH AMERICA: OTHER REAGENTS & KITS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 139. TABLE 78 EUROPE: OTHER REAGENTS & KITS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 140. TABLE 79 ASIA PACIFIC: OTHER REAGENTS & KITS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 140. TABLE 80 LATIN AMERICA: OTHER REAGENTS & KITS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 141. TABLE 81 KEY ANALYZERS AVAILABLE IN MARKET 142. TABLE 82 IMMUNOASSAY ANALYZERS MARKET, BY REGION, 2024–2031 (USD MILLION) 143. TABLE 83 NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 143. TABLE 84 EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 144. TABLE 85 ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 144. TABLE 86 LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 145. TABLE 87 IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 146. TABLE 88 OPEN-ENDED IMMUNOASSAY SYSTEMS MARKET, BY REGION,. 2024–2031 (USD MILLION) 146. TABLE 89 NORTH AMERICA: OPEN-ENDED IMMUNOASSAY SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 147. TABLE 90 EUROPE: OPEN-ENDED IMMUNOASSAY SYSTEMS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 147. TABLE 91 ASIA PACIFIC: OPEN-ENDED IMMUNOASSAY SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 148. TABLE 92 LATIN AMERICA: OPEN-ENDED IMMUNOASSAY SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 148. TABLE 93 CLOSED-ENDED IMMUNOASSAY SYSTEMS MARKET, BY REGION,. 2024–2031 (USD MILLION) 149. TABLE 94 NORTH AMERICA: CLOSED-ENDED IMMUNOASSAY SYSTEMS MARKET,. BY COUNTRY, 2024–2031 (USD MILLION) 149. TABLE 95 EUROPE: CLOSED-ENDED IMMUNOASSAY SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 150. TABLE 96 ASIA PACIFIC: CLOSED-ENDED IMMUNOASSAY SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 150. TABLE 97 LATIN AMERICA: CLOSED-ENDED IMMUNOASSAY SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 151. TABLE 98 IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,. 2024–2031 (USD MILLION) 151. TABLE 99 IMMUNOASSAY ANALYZERS MARKET FOR RENTAL PURCHASE, BY REGION,. 2024–2031 (USD MILLION) 152. TABLE 100 NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET FOR RENTAL PURCHASE, BY COUNTRY, 2024–2031 (USD MILLION) 153. TABLE 101 EUROPE: IMMUNOASSAY ANALYZERS MARKET FOR RENTAL PURCHASE,. BY COUNTRY, 2024–2031 (USD MILLION) 153. TABLE 102 ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET FOR RENTAL PURCHASE,. BY COUNTRY, 2024–2031 (USD MILLION) 154. TABLE 103 LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET FOR RENTAL PURCHASE,. BY COUNTRY, 2024–2031 (USD MILLION) 154. TABLE 104 IMMUNOASSAY ANALYZERS MARKET FOR OUTRIGHT PURCHASE, BY REGION, 2024–2031 (USD MILLION) 155. TABLE 105 NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET FOR OUTRIGHT PURCHASE, BY COUNTRY, 2024–2031 (USD MILLION) 155. TABLE 106 EUROPE: IMMUNOASSAY ANALYZERS MARKET FOR OUTRIGHT PURCHASE,. BY COUNTRY, 2024–2031 (USD MILLION) 156. TABLE 107 ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET FOR OUTRIGHT PURCHASE,. BY COUNTRY, 2024–2031 (USD MILLION) 156. TABLE 108 LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET FOR OUTRIGHT PURCHASE, BY COUNTRY, 2024–2031 (USD MILLION) 157. TABLE 109 IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 159. TABLE 110 KEY ELISA TECHNOLOGIES AVAILABLE IN MARKET 160. TABLE 111 IMMUNOASSAY MARKET FOR ELISA, BY REGION, 2024–2031 (USD MILLION) 161. TABLE 112 NORTH AMERICA: IMMUNOASSAY MARKET FOR ELISA, BY COUNTRY,. 2024–2031 (USD MILLION) 161. TABLE 113 EUROPE: IMMUNOASSAY MARKET FOR ELISA, BY COUNTRY,. 2024–2031 (USD MILLION) 162. TABLE 114 ASIA PACIFIC: IMMUNOASSAY MARKET FOR ELISA, BY COUNTRY,. 2024–2031 (USD MILLION) 162. TABLE 115 LATIN AMERICA: IMMUNOASSAY MARKET FOR ELISA, BY COUNTRY,. 2024–2031 (USD MILLION) 163. TABLE 116 IMMUNOASSAY MARKET FOR CLIA, BY REGION, 2024–2031 (USD MILLION) 164. TABLE 117 NORTH AMERICA: IMMUNOASSAY MARKET FOR CLIA, BY COUNTRY,. 2024–2031 (USD MILLION) 164. TABLE 118 EUROPE: IMMUNOASSAY MARKET FOR CLIA, BY COUNTRY,. 2024–2031 (USD MILLION) 165. TABLE 119 ASIA PACIFIC: IMMUNOASSAY MARKET FOR CLIA, BY COUNTRY,. 2024–2031 (USD MILLION) 165. TABLE 120 LATIN AMERICA: IMMUNOASSAY MARKET FOR CLIA, BY COUNTRY,. 2024–2031 (USD MILLION) 166. TABLE 121 IMMUNOASSAY MARKET FOR IFA, BY REGION, 2024–2031 (USD MILLION) 167. TABLE 122 NORTH AMERICA: IMMUNOASSAY MARKET FOR IFA, BY COUNTRY,. 2024–2031 (USD MILLION) 167. TABLE 123 EUROPE: IMMUNOASSAY MARKET FOR IFA, BY COUNTRY,. 2024–2031 (USD MILLION) 168. TABLE 124 ASIA PACIFIC: IMMUNOASSAY MARKET FOR IFA, BY COUNTRY,. 2024–2031 (USD MILLION) 168. TABLE 125 LATIN AMERICA: IMMUNOASSAY MARKET FOR IFA, BY COUNTRY,. 2024–2031 (USD MILLION) 169. TABLE 126 KEY RAPID TESTS AVAILABLE IN MARKET 169. TABLE 127 IMMUNOASSAY MARKET FOR RAPID TESTS, BY REGION,. 2024–2031 (USD MILLION) 170. TABLE 128 NORTH AMERICA: IMMUNOASSAY MARKET FOR RAPID TESTS, BY COUNTRY, 2024–2031 (USD MILLION) 170. TABLE 129 EUROPE: IMMUNOASSAY MARKET FOR RAPID TESTS, BY COUNTRY,. 2024–2031 (USD MILLION) 171. TABLE 130 ASIA PACIFIC: IMMUNOASSAY MARKET FOR RAPID TESTS, BY COUNTRY,. 2024–2031 (USD MILLION) 171. TABLE 131 LATIN AMERICA: IMMUNOASSAY MARKET FOR RAPID TESTS, BY COUNTRY,. 2024–2031 (USD MILLION) 172. TABLE 132 KEY WESTERN BLOTTING SYSTEMS AVAILABLE IN MARKET 172. TABLE 133 IMMUNOASSAY MARKET FOR WESTERN BLOTTING, BY REGION,. 2024–2031 (USD MILLION) 173. TABLE 134 NORTH AMERICA: IMMUNOASSAY MARKET FOR WESTERN BLOTTING,. BY COUNTRY, 2024–2031 (USD MILLION) 173. TABLE 135 EUROPE: IMMUNOASSAY MARKET FOR WESTERN BLOTTING, BY COUNTRY,. 2024–2031 (USD MILLION) 174. TABLE 136 ASIA PACIFIC: IMMUNOASSAY MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2024–2031 (USD MILLION) 174. TABLE 137 LATIN AMERICA: IMMUNOASSAY MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2024–2031 (USD MILLION) 175. TABLE 138 IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES, BY REGION,. 2024–2031 (USD MILLION) 176. TABLE 139 NORTH AMERICA: IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES,. BY COUNTRY, 2024–2031 (USD MILLION) 176. TABLE 140 EUROPE: IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 177. TABLE 141 ASIA PACIFIC: IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES,. BY COUNTRY, 2024–2031 (USD MILLION) 177. TABLE 142 LATIN AMERICA: IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES,. BY COUNTRY, 2024–2031 (USD MILLION) 178. TABLE 143 IMMUNOASSAY MARKET, BY SPECIMEN, 2024–2031 (USD MILLION) 180. TABLE 144 IMMUNOASSAY MARKET FOR BLOOD SPECIMENS, BY REGION,. 2024–2031 (USD MILLION) 181. TABLE 145 NORTH AMERICA: IMMUNOASSAY MARKET FOR BLOOD SPECIMENS, BY COUNTRY, 2024–2031 (USD MILLION) 182. TABLE 146 EUROPE: IMMUNOASSAY MARKET FOR BLOOD SPECIMENS, BY COUNTRY,. 2024–2031 (USD MILLION) 182. TABLE 147 ASIA PACIFIC: IMMUNOASSAY MARKET FOR BLOOD SPECIMENS, BY COUNTRY, 2024–2031 (USD MILLION) 183. TABLE 148 LATIN AMERICA: IMMUNOASSAY MARKET FOR BLOOD SPECIMENS, BY COUNTRY, 2024–2031 (USD MILLION) 183. TABLE 149 IMMUNOASSAY MARKET FOR SALIVA SPECIMENS, BY REGION,. 2024–2031 (USD MILLION) 184. TABLE 150 NORTH AMERICA: IMMUNOASSAY MARKET FOR SALIVA SPECIMENS, BY COUNTRY, 2024–2031 (USD MILLION) 185. TABLE 151 EUROPE: IMMUNOASSAY MARKET FOR SALIVA SPECIMENS, BY COUNTRY,. 2024–2031 (USD MILLION) 185. TABLE 152 ASIA PACIFIC: IMMUNOASSAY MARKET FOR SALIVA SPECIMENS, BY COUNTRY, 2024–2031 (USD MILLION) 186. TABLE 153 LATIN AMERICA: IMMUNOASSAY MARKET FOR SALIVA SPECIMENS, BY COUNTRY, 2024–2031 (USD MILLION) 186. TABLE 154 IMMUNOASSAY MARKET FOR URINE SPECIMENS, BY REGION,. 2024–2031 (USD MILLION) 187. TABLE 155 NORTH AMERICA: IMMUNOASSAY MARKET FOR URINE SPECIMENS, BY COUNTRY, 2024–2031 (USD MILLION) 188. TABLE 156 EUROPE: IMMUNOASSAY MARKET FOR URINE SPECIMENS, BY COUNTRY,. 2024–2031 (USD MILLION) 188. TABLE 157 ASIA PACIFIC: IMMUNOASSAY MARKET FOR URINE SPECIMENS, BY COUNTRY, 2024–2031 (USD MILLION) 189. TABLE 158 LATIN AMERICA: IMMUNOASSAY MARKET FOR URINE SPECIMENS, BY COUNTRY, 2024–2031 (USD MILLION) 189. TABLE 159 IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY REGION,. 2024–2031 (USD MILLION) 190. TABLE 160 NORTH AMERICA: IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2024–2031 (USD MILLION) 191. TABLE 161 EUROPE: IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY COUNTRY,. 2024–2031 (USD MILLION) 191. TABLE 162 ASIA PACIFIC: IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2024–2031 (USD MILLION) 192. TABLE 163 LATIN AMERICA: IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2024–2031 (USD MILLION) 192. TABLE 164 IMMUNOASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 194. TABLE 165 IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2024–2031 (USD MILLION) 195. TABLE 166 NORTH AMERICA: IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES,. BY COUNTRY, 2024–2031 (USD MILLION) 196. TABLE 167 EUROPE: IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 196. TABLE 168 ASIA PACIFIC: IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 197. TABLE 169 LATIN AMERICA: IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES,. BY COUNTRY, 2024–2031 (USD MILLION) 197. TABLE 170 IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY REGION,. 2024–2031 (USD MILLION) 198. TABLE 171 NORTH AMERICA: IMMUNOASSAY MARKET FOR ENDOCRINOLOGY,. BY COUNTRY, 2024–2031 (USD MILLION) 199. TABLE 172 EUROPE: IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY COUNTRY,. 2024–2031 (USD MILLION) 199. TABLE 173 ASIA PACIFIC: IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 200. TABLE 174 LATIN AMERICA: IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 200. TABLE 175 KEY PRODUCTS AVAILABLE FOR CARDIOLOGY APPLICATIONS 202. TABLE 176 IMMUNOASSAY MARKET FOR CARDIOLOGY, BY REGION,. 2024–2031 (USD MILLION) 202. TABLE 177 NORTH AMERICA: IMMUNOASSAY MARKET FOR CARDIOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 203. TABLE 178 EUROPE: IMMUNOASSAY MARKET FOR CARDIOLOGY, BY COUNTRY,. 2024–2031 (USD MILLION) 203. TABLE 179 ASIA PACIFIC: IMMUNOASSAY MARKET FOR CARDIOLOGY, BY COUNTRY,. 2024–2031 (USD MILLION) 204. TABLE 180 LATIN AMERICA: IMMUNOASSAY MARKET FOR CARDIOLOGY, BY COUNTRY,. 2024–2031 (USD MILLION) 204. TABLE 181 IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS, BY REGION,. 2024–2031 (USD MILLION) 205. TABLE 182 NORTH AMERICA: IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS,. BY COUNTRY, 2024–2031 (USD MILLION) 206. TABLE 183 EUROPE: IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 206. TABLE 184 ASIA PACIFIC: IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS,. BY COUNTRY, 2024–2031 (USD MILLION) 207. TABLE 185 LATIN AMERICA: IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS,. BY COUNTRY, 2024–2031 (USD MILLION) 207. TABLE 186 IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS, BY REGION,. 2024–2031 (USD MILLION) 208. TABLE 187 NORTH AMERICA: IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS,. BY COUNTRY, 2024–2031 (USD MILLION) 209. TABLE 188 EUROPE: IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION) 209. TABLE 189 ASIA PACIFIC: IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS,. BY COUNTRY, 2024–2031 (USD MILLION) 210. TABLE 190 LATIN AMERICA: IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS,. BY COUNTRY, 2024–2031 (USD MILLION) 210. TABLE 191 IMMUNOASSAY MARKET FOR ONCOLOGY, BY REGION, 2024–2031 (USD MILLION) 212. TABLE 192 NORTH AMERICA: IMMUNOASSAY MARKET FOR ONCOLOGY, BY COUNTRY,. 2024–2031 (USD MILLION) 212. TABLE 193 EUROPE: IMMUNOASSAY MARKET FOR ONCOLOGY, BY COUNTRY,. 2024–2031 (USD MILLION) 213. TABLE 194 ASIA PACIFIC: IMMUNOASSAY MARKET FOR ONCOLOGY, BY COUNTRY,. 2024–2031 (USD MILLION) 213. TABLE 195 LATIN AMERICA: IMMUNOASSAY MARKET FOR ONCOLOGY, BY COUNTRY,. 2024–2031 (USD MILLION) 214. TABLE 196 KEY PRODUCTS AVAILABLE FOR BONE & MINERAL DISORDERS 215. TABLE 197 IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS, BY REGION,. 2024–2031 (USD MILLION) 215. TABLE 198 NORTH AMERICA: IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS,. BY COUNTRY, 2024–2031 (USD MILLION) 216. TABLE 199 EUROPE: IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS,. BY COUNTRY, 2024–2031 (USD MILLION) 216. TABLE 200 ASIA PACIFIC: IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS,. BY COUNTRY, 2024–2031 (USD MILLION) 217. TABLE 201 LATIN AMERICA: IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS,. BY COUNTRY, 2024–2031 (USD MILLION) 217. TABLE 202 KEY PRODUCTS AVAILABLE FOR DRUG MONITORING & TESTING 218. TABLE 203 KEY IMMUNOASSAY PRODUCTS AVAILABLE FOR DRUG MONITORING & TESTING 219. TABLE 204 IMMUNOASSAY MARKET FOR DRUG MONITORING & TESTING, BY REGION,. 2024–2031 (USD MILLION) 219. TABLE 205 NORTH AMERICA: IMMUNOASSAY MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 219. TABLE 206 EUROPE: IMMUNOASSAY MARKET FOR DRUG MONITORING & TESTING,. BY COUNTRY, 2024–2031 (USD MILLION) 220. TABLE 207 ASIA PACIFIC: IMMUNOASSAY MARKET FOR DRUG MONITORING & TESTING,. BY COUNTRY, 2024–2031 (USD MILLION) 220. TABLE 208 LATIN AMERICA: IMMUNOASSAY MARKET FOR DRUG MONITORING & TESTING,. BY COUNTRY, 2024–2031 (USD MILLION) 221. TABLE 209 IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY REGION,. 2024–2031 (USD MILLION) 222. TABLE 210 NORTH AMERICA: IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY COUNTRY, 2024–2031 (USD MILLION) 222. TABLE 211 EUROPE: IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY COUNTRY,. 2024–2031 (USD MILLION) 223. TABLE 212 ASIA PACIFIC: IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY COUNTRY, 2024–2031 (USD MILLION) 223. TABLE 213 LATIN AMERICA: IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY COUNTRY, 2024–2031 (USD MILLION) 224. TABLE 214 KEY PRODUCTS AVAILABLE FOR NEWBORN SCREENING 224. TABLE 215 IMMUNOASSAY MARKET FOR NEWBORN SCREENING, BY REGION,. 2024–2031 (USD MILLION) 225. TABLE 216 NORTH AMERICA: IMMUNOASSAY MARKET FOR NEWBORN SCREENING,. BY COUNTRY, 2024–2031 (USD MILLION) 225. TABLE 217 EUROPE: IMMUNOASSAY MARKET FOR NEWBORN SCREENING, BY COUNTRY, 2024–2031 (USD MILLION) 226. TABLE 218 ASIA PACIFIC: IMMUNOASSAY MARKET FOR NEWBORN SCREENING, BY COUNTRY, 2024–2031 (USD MILLION) 226. TABLE 219 LATIN AMERICA: IMMUNOASSAY MARKET FOR NEWBORN SCREENING,. BY COUNTRY, 2024–2031 (USD MILLION) 227. TABLE 220 IMMUNOASSAY MARKET FOR OTHER APPLICATIONS, BY REGION,. 2024–2031 (USD MILLION) 228. TABLE 221 NORTH AMERICA: IMMUNOASSAY MARKET FOR OTHER APPLICATIONS,. BY COUNTRY, 2024–2031 (USD MILLION) 228. TABLE 222 EUROPE: IMMUNOASSAY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 229. TABLE 223 ASIA PACIFIC: IMMUNOASSAY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 229. TABLE 224 LATIN AMERICA: IMMUNOASSAY MARKET FOR OTHER APPLICATIONS,. BY COUNTRY, 2024–2031 (USD MILLION) 230. TABLE 225 IMMUNOASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 232. TABLE 226 IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS, BY REGION,. 2024–2031 (USD MILLION) 233. TABLE 227 NORTH AMERICA: IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS,. BY COUNTRY, 2024–2031 (USD MILLION) 234. TABLE 228 EUROPE: IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2024–2031 (USD MILLION) 234. TABLE 229 ASIA PACIFIC: IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS,. BY COUNTRY, 2024–2031 (USD MILLION) 235. TABLE 230 LATIN AMERICA: IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS,. BY COUNTRY, 2024–2031 (USD MILLION) 235. TABLE 231 IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY REGION,. 2024–2031 (USD MILLION) 237. TABLE 232 NORTH AMERICA: IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES,. BY COUNTRY, 2024–2031 (USD MILLION) 237. TABLE 233 EUROPE: IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 238. TABLE 234 ASIA PACIFIC: IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES,. BY COUNTRY, 2024–2031 (USD MILLION) 238. TABLE 235 LATIN AMERICA: IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES,. BY COUNTRY, 2024–2031 (USD MILLION) 239. TABLE 236 IMMUNOASSAY MARKET FOR HOME CARE SETTINGS, BY REGION,. 2024–2031 (USD MILLION) 240. TABLE 237 NORTH AMERICA: IMMUNOASSAY MARKET FOR HOME CARE SETTINGS,. BY COUNTRY, 2024–2031 (USD MILLION) 240. TABLE 238 EUROPE: IMMUNOASSAY MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2024–2031 (USD MILLION) 241. TABLE 239 ASIA PACIFIC: IMMUNOASSAY MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2024–2031 (USD MILLION) 241. TABLE 240 LATIN AMERICA: IMMUNOASSAY MARKET FOR HOME CARE SETTINGS,. BY COUNTRY, 2024–2031 (USD MILLION) 242. TABLE 241 IMMUNOASSAY MARKET FOR BLOOD BANKS, BY REGION,. 2024–2031 (USD MILLION) 243. TABLE 242 NORTH AMERICA: IMMUNOASSAY MARKET FOR BLOOD BANKS, BY COUNTRY, 2024–2031 (USD MILLION) 243. TABLE 243 EUROPE: IMMUNOASSAY MARKET FOR BLOOD BANKS, BY COUNTRY,. 2024–2031 (USD MILLION) 244. TABLE 244 ASIA PACIFIC: IMMUNOASSAY MARKET FOR BLOOD BANKS, BY COUNTRY,. 2024–2031 (USD MILLION) 244. TABLE 245 LATIN AMERICA: IMMUNOASSAY MARKET FOR BLOOD BANKS, BY COUNTRY, 2024–2031 (USD MILLION) 245. TABLE 246 IMMUNOASSAY MARKET, BY REGION, 2024–2031 (USD MILLION) 247. TABLE 247 NORTH AMERICA: IMMUNOASSAY MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 249. TABLE 248 NORTH AMERICA: IMMUNOASSAY MARKET, BY PRODUCT,. 2024–2031 (USD MILLION) 249. TABLE 249 NORTH AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,. 2024–2031 (USD MILLION) 250. TABLE 250 NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE,. 2024–2031 (USD MILLION) 250. TABLE 251 NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2024–2031 (USD MILLION) 251. TABLE 252 NORTH AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY,. 2024–2031 (USD MILLION) 251. TABLE 253 NORTH AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN,. 2024–2031 (USD MILLION) 252. TABLE 254 NORTH AMERICA: IMMUNOASSAY MARKET, BY APPLICATION,. 2024–2031 (USD MILLION) 252. TABLE 255 NORTH AMERICA: IMMUNOASSAY MARKET, BY END USER,. 2024–2031 (USD MILLION) 253. TABLE 256 US: NUMBER OF IN VITRO DIAGNOSTIC TESTS CONDUCTED,. 2022–2031 (BILLION UNITS) 254. TABLE 257 US: IMMUNOASSAY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 255. TABLE 258 US: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,. 2024–2031 (USD MILLION) 255. TABLE 259 US: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 256. TABLE 260 US: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,. 2024–2031 (USD MILLION) 256. TABLE 261 US: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 257. TABLE 262 US: IMMUNOASSAY MARKET, BY SPECIMEN, 2024–2031 (USD MILLION) 257. TABLE 263 US: IMMUNOASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 258. TABLE 264 US: IMMUNOASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 258. TABLE 265 CANADA: ESTIMATED PREVALENCE OF DIABETES, 2025 VS. 2034 259. TABLE 266 CANADA: IMMUNOASSAY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 260. TABLE 267 CANADA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,. 2024–2031 (USD MILLION) 260. TABLE 268 CANADA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE,. 2024–2031 (USD MILLION) 261. TABLE 269 CANADA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,. 2024–2031 (USD MILLION) 261. TABLE 270 CANADA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 262. TABLE 271 CANADA: IMMUNOASSAY MARKET, BY SPECIMEN, 2024–2031 (USD MILLION) 262. TABLE 272 CANADA: IMMUNOASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 263. TABLE 273 CANADA: IMMUNOASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 263. TABLE 274 EUROPE: IMMUNOASSAY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 264. TABLE 275 EUROPE: IMMUNOASSAY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 265. TABLE 276 EUROPE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,. 2024–2031 (USD MILLION) 265. TABLE 277 EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE,. 2024–2031 (USD MILLION) 266. TABLE 278 EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,. 2024–2031 (USD MILLION) 266. TABLE 279 EUROPE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 267. TABLE 280 EUROPE: IMMUNOASSAY MARKET, BY SPECIMEN, 2024–2031 (USD MILLION) 267. TABLE 281 EUROPE: IMMUNOASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 268. TABLE 282 EUROPE: IMMUNOASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 268. TABLE 283 GERMANY: IMMUNOASSAY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 269. TABLE 284 GERMANY: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,. 2024–2031 (USD MILLION) 270. TABLE 285 GERMANY: IMMUNOASSAY ANALYZERS MARKET, BY TYPE,. 2024–2031 (USD MILLION) 270. TABLE 286 GERMANY: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,. 2024–2031 (USD MILLION) 271. TABLE 287 GERMANY: IMMUNOASSAY MARKET, BY TECHNOLOGY,. 2024–2031 (USD MILLION) 271. TABLE 288 GERMANY: IMMUNOASSAY MARKET, BY SPECIMEN, 2024–2031 (USD MILLION) 272. TABLE 289 GERMANY: IMMUNOASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 272. TABLE 290 GERMANY: IMMUNOASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 273. TABLE 291 ITALY: IMMUNOASSAY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 274. TABLE 292 ITALY: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,. 2024–2031 (USD MILLION) 274. TABLE 293 ITALY: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 275. TABLE 294 ITALY: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,. 2024–2031 (USD MILLION) 275. TABLE 295 ITALY: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 276. TABLE 296 ITALY: IMMUNOASSAY MARKET, BY SPECIMEN, 2024–2031 (USD MILLION) 276. TABLE 297 ITALY: IMMUNOASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 277. TABLE 298 ITALY: IMMUNOASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 277. TABLE 299 FRANCE: IMMUNOASSAY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 278. TABLE 300 FRANCE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,. 2024–2031 (USD MILLION) 279. TABLE 301 FRANCE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE,. 2024–2031 (USD MILLION) 279. TABLE 302 FRANCE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,. 2024–2031 (USD MILLION) 280. TABLE 303 FRANCE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 280. TABLE 304 FRANCE: IMMUNOASSAY MARKET, BY SPECIMEN, 2024–2031 (USD MILLION) 281. TABLE 305 FRANCE: IMMUNOASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 281. TABLE 306 FRANCE: IMMUNOASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 282. TABLE 307 UK: IMMUNOASSAY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 283. TABLE 308 UK: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,. 2024–2031 (USD MILLION) 284.
SummaryThe global immunoassay market is estimated to be valued at USD 31.65 billion in 2026 and is projected to reach USD 44.49 billion by 2031, registering a CAGR of 7.0% during the forecast period. Market growth is primarily driven by the rising prevalence of chronic and infectious diseases, continued technological advancements in immunoassay systems, supportive government initiatives, and increasing demand for drug and alcohol screening driven by stringent regulatory requirements. By product, the reagents & kits segment accounted for the largest share of the immunoassay market in 2025. By technology, the chemiluminescence immunoassay segment is expected to grow at a considerable rate during the forecast period. Asia Pacific is expected to register the fastest growth rate in the immunoassay market between 2026 and 2031. The breakdown of primary participants in the immunoassay market is as follows: Key players in the immunoassay market are Abbott Laboratories (US), F. Hoffmann-La Roche Ltd (Switzerland), Siemens Healthineers AG (Germany), Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), PerkinElmer, Inc. (US), Becton, Dickinson and Company (US), DiaSorin S.p.A. (Italy), Bio-Rad Laboratories, Inc. (US), QuidelOrtho Corporation (US), bioMérieux (France), QIAGEN N.V. (Germany), Sysmex Corporation (Japan), Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China), Agilent Technologies (US), Merck KGaA (Germany), Meridian Bioscience (US), Bio-Techne (US), Cellabs (Australia), Abnova Corporation (Taiwan), J. Mitra & Co. Pvt. Ltd. (India), Tosoh Corporation (Japan), Cell Sciences (US), Enzo Biochem (US), Creative Diagnostics (US), Boster Biological Technology (US), Elabscience (US), WAK-Chemie Medical GmbH (Germany), SeraCare (US), Epitope Diagnostics Inc. (US), Kamiya Biomedical Company (US), Gyros Protein Technologies (Sweden), Trivitron Healthcare (India), InBios International Inc. (US), and Maccura Biotechnology Co., Ltd. (China). Research Coverage: The report covers detailed information on major factors, such as drivers, restraints, opportunities, and challenges influencing immunoassay market growth. A detailed analysis of key industry players provides insights into their business overview, solutions, and key strategies, including partnerships, collaborations, expansions, agreements, product launches, and recent market developments. This report covers the competitive analysis of upcoming startups in the immunoassay ecosystem. Reasons to Buy This Report: The report provides insights into the following pointers: Table of Contents1 INTRODUCTION 38 2 EXECUTIVE SUMMARY 43 3 PREMIUM INSIGHTS 48 4 MARKET OVERVIEW 52 5 INDUSTRY TRENDS 71 6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 91 7 SUSTAINABILITY & REGULATORY LANDSCAPE 98 8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 113 9 IMMUNOASSAY MARKET, BY PRODUCT 118 10 IMMUNOASSAY MARKET, BY TECHNOLOGY 158 11 IMMUNOASSAY MARKET, BY SPECIMEN 179 12 IMMUNOASSAY MARKET, BY APPLICATION 193 13 IMMUNOASSAY MARKET, BY END USER 231 14 IMMUNOASSAY MARKET, BY REGION 246 15 IMMUNOASSAYS MARKET: VOLUME ANALYSIS 361 16 COMPETITIVE LANDSCAPE 362 17 COMPANY PROFILES 380 18 RESEARCH METHODOLOGY 459 19 APPENDIX 472 List of Tables/GraphsFIGURE 1 IMMUNOASSAY MARKET SEGMENTATION & REGIONAL SCOPE 39.FIGURE 2 IMMUNOASSAY MARKET: YEARS CONSIDERED 41. FIGURE 3 KEY INSIGHTS & MARKET HIGHLIGHTS 43. FIGURE 4 GLOBAL IMMUNOASSAY MARKET, 2024–2031 44. FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN IMMUNOASSAY MARKET, 2024–2026 44. FIGURE 6 DISRUPTIVE TRENDS IMPACTING GROWTH OF IMMUNOASSAY MARKET 45. FIGURE 7 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS IN. IMMUNOASSAY MARKET, 2025 46. FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 47. FIGURE 9 HIGH PREVALENCE OF CHRONIC AND INFECTIOUS DISEASES TO DRIVE MARKET 48. FIGURE 10 REAGENTS & KITS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 49. FIGURE 11 CLIA SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 49. FIGURE 12 BLOOD SAMPLES SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 50. FIGURE 13 INFECTIOUS DISEASES SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 50. FIGURE 14 HOSPITALS & CLINICS SEGMENT TO COMMAND LARGEST. SHARE DURING FORECAST PERIOD 51. FIGURE 15 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 51. FIGURE 16 IMMUNOASSAY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,. AND CHALLENGES 53. FIGURE 17 IMMUNOASSAY MARKET: PORTER’S FIVE FORCES ANALYSIS 71. FIGURE 18 IMMUNOASSAY MARKET: SUPPLY CHAIN ANALYSIS 76. FIGURE 19 IMMUNOASSAY MARKET: VALUE CHAIN ANALYSIS 77. FIGURE 20 IMMUNOASSAY MARKET: ECOSYSTEM ANALYSIS 78. FIGURE 21 IMMUNOASSAY MARKET: TRENDS/DISRUPTIONS IMPACTING. CUSTOMERS’ BUSINESSES 85. FIGURE 22 NUMBER OF DEALS & FUNDING ACTIVITIES IN IMMUNOASSAY MARKET 86. FIGURE 23 TOP 10 PATENT OWNERS/APPLICANTS IN IMMUNOASSAY MARKET,. JANUARY 2015–DECEMBER 2024 93. FIGURE 24 MARKET POTENTIAL OF AI IN IMMUNOASSAY MARKET 96. FIGURE 25 US: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 99. FIGURE 26 CANADA: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 100. FIGURE 27 JAPAN: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 102. FIGURE 28 INDIA: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 104. FIGURE 29 MEXICO: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 106. FIGURE 30 BRAZIL: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 108. FIGURE 31 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER 113. FIGURE 32 KEY BUYING CRITERIA, BY END USER 114. FIGURE 33 NORTH AMERICA: IMMUNOASSAY MARKET SNAPSHOT 248. FIGURE 34 ASIA PACIFIC: IMMUNOASSAY MARKET SNAPSHOT 302. FIGURE 35 REVENUE ANALYSIS OF KEY PLAYERS IN IMMUNOASSAY MARKET,. 2023–2025 (USD MILLION) 364. FIGURE 36 IMMUNOASSAY MARKET SHARE ANALYSIS, 2025 (GLOBAL) 365. FIGURE 37 IMMUNOASSAY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 367. FIGURE 38 IMMUNOASSAY MARKET: COMPANY FOOTPRINT 368. FIGURE 39 IMMUNOASSAY MARKET: COMPANY EVALUATION MATRIX. (STARTUPS/SMES), 2025 373. FIGURE 40 EV/EBITDA OF KEY VENDORS 376. FIGURE 41 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA. OF KEY VENDORS 376. FIGURE 42 IMMUNOASSAY MARKET: BRAND/PRODUCT COMPARISON 377. FIGURE 43 ABBOTT: COMPANY SNAPSHOT (2025) 381. FIGURE 44 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2025) 387. FIGURE 45 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2025) 393. FIGURE 46 DANAHER CORPORATION: COMPANY SNAPSHOT (2025) 398. FIGURE 47 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025) 405. FIGURE 48 REVVITY INC.: COMPANY SNAPSHOT (2025) 410. FIGURE 49 WATERS CORPORATION: COMPANY SNAPSHOT (2025) 413. FIGURE 50 DIASORIN S.P.A.: COMPANY SNAPSHOT (2025) 416. FIGURE 51 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2025) 421. FIGURE 52 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2025) 425. FIGURE 53 BIOMÉRIEUX: COMPANY SNAPSHOT (2025) 430. FIGURE 54 QIAGEN: COMPANY SNAPSHOT (2025) 434. FIGURE 55 SYSMEX CORPORATION: COMPANY SNAPSHOT (2025) 437. FIGURE 56 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025) 442. FIGURE 57 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.:. COMPANY SNAPSHOT (2025) 444. FIGURE 58 IMMUNOASSAY MARKET: RESEARCH DESIGN 459. FIGURE 59 IMMUNOASSAY MARKET: KEY DATA FROM SECONDARY SOURCES 461. FIGURE 60 IMMUNOASSAY MARKET: KEY PRIMARY SOURCES 461. FIGURE 61 IMMUNOASSAY MARKET: KEY INSIGHTS FROM INDUSTRY EXPERTS 464. FIGURE 62 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND. DEMAND-SIDE PARTICIPANTS 464. FIGURE 63 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,. DESIGNATION, AND REGION 465. FIGURE 64 IMMUNOASSAY MARKET: COMPANY REVENUE ESTIMATION. (REVENUE SHARE ANALYSIS) 466. FIGURE 65 IMMUNOASSAY MARKET: CAGR PROJECTIONS (SUPPLY-SIDE ANALYSIS) 467. FIGURE 66 IMMUNOASSAY MARKET: TOP-DOWN APPROACH 468. FIGURE 67 IMMUNOASSAY MARKET: DATA TRIANGULATION METHODOLOGY 469. TABLE 1 IMMUNOASSAY MARKET: INCLUSIONS & EXCLUSIONS 40. TABLE 2 INCREASING INCIDENCE OF CANCER, BY REGION, 2024 VS. 2040 (MILLION) 55. TABLE 3 NUMBER OF NEW CANCER CASES, BY CANCER TYPE, 2024 55. TABLE 4 DETECTION TIME OF DRUG OR DRUG CLASS IN URINE TESTING 56. TABLE 5 NEW TESTS LAUNCHED BY KEY PLAYERS, 2023–2026 63. TABLE 6 LAB-ON-CHIP IMMUNOASSAYS/DEVICES/SYSTEMS OFFERED BY KEY PLAYERS 63. TABLE 7 IMMUNOASSAY MARKET: PORTER’S FIVE FORCES 71. TABLE 8 GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2023–2030 73. TABLE 9 NORTH AMERICA: MACROECONOMIC INDICATORS 74. TABLE 10 EUROPE: MACROECONOMIC INDICATORS 74. TABLE 11 ASIA PACIFIC: MACROECONOMIC INDICATORS 75. TABLE 12 LATIN AMERICA: MACROECONOMIC INDICATORS 75. TABLE 13 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS 75. TABLE 14 IMMUNOASSAY MARKET: ROLE OF COMPANIES IN ECOSYSTEM 79. TABLE 15 AVERAGE SELLING PRICE TREND OF IMMUNOASSAY PRODUCTS,. BY KEY PLAYER, 2024–2026 (USD) 80. TABLE 16 AVERAGE SELLING PRICE TREND OF CLINICAL IMMUNOASSAY ANALYZERS,. BY REGION, 2024–2026 (USD) 81. TABLE 17 AVERAGE SELLING PRICE TREND OF IMMUNOASSAY PRODUCTS, BY TYPE,. 2024–2026 (USD) 82. TABLE 18 IMPORT DATA FOR HS CODE 382200-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION) 83. TABLE 19 EXPORT DATA FOR HS CODE 382200-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION) 84. TABLE 20 IMMUNOASSAY MARKET: KEY CONFERENCES & EVENTS, 2026–2027 84. TABLE 21 US-ADJUSTED RECIPROCAL TARIFF RATES 87. TABLE 22 KEY PATENTS IN IMMUNOASSAY, 2023–2026 94. TABLE 23 KEY COMPANIES IMPLEMENTING AI IN IMMUNOASSAY MARKET 97. TABLE 24 US: CLASSIFICATION AND RISK LEVEL OF IMMUNOASSAY PRODUCTS 98. TABLE 25 EUROPE: CLASSIFICATION AND RISK LEVEL OF IN VITRO DIAGNOSTIC DEVICES 101. TABLE 26 RUSSIA: CLASSIFICATION AND RISK LEVEL OF IN VITRO DIAGNOSTIC DEVICES 101. TABLE 27 JAPAN: CLASSIFICATION OF IN VITRO DIAGNOSTIC REAGENTS 102. TABLE 28 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 103. TABLE 29 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 103. TABLE 30 INDONESIA: REGISTRATION PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 104. TABLE 31 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 105. TABLE 32 SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 106. TABLE 33 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 107. TABLE 34 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,. AND OTHER ORGANIZATIONS 108. TABLE 35 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,. AND OTHER ORGANIZATIONS 109. TABLE 36 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,. AND OTHER ORGANIZATIONS 109. TABLE 37 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,. AND OTHER ORGANIZATIONS 109. TABLE 38 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES,. AND OTHER ORGANIZATIONS 110. TABLE 39 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER (%) 113. TABLE 40 KEY BUYING CRITERIA, BY END USER 114. TABLE 41 ADOPTION BARRIERS & INTERNAL CHALLENGES 115. TABLE 42 IMMUNOASSAY MARKET: UNMET NEEDS IN VARIOUS END-USE INDUSTRIES 116. TABLE 43 IMMUNOASSAY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 119. TABLE 44 KEY REAGENTS & KITS AVAILABLE IN MARKET 120. TABLE 45 IMMUNOASSAY REAGENTS & KITS MARKET, BY REGION,. 2024–2031 (USD MILLION) 121. TABLE 46 IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2024–2031 (USD MILLION) 121. TABLE 47 NORTH AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET,. BY COUNTRY, 2024–2031 (USD MILLION) 122. TABLE 48 EUROPE: IMMUNOASSAY REAGENTS & KITS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 122. TABLE 49 ASIA PACIFIC: IMMUNOASSAY REAGENTS & KITS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 123. TABLE 50 LATIN AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 123. TABLE 51 ELISA REAGENTS & KITS MARKET, BY REGION, 2024–2031 (USD MILLION) 125. TABLE 52 NORTH AMERICA: ELISA REAGENTS & KITS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 125. TABLE 53 EUROPE: ELISA REAGENTS & KITS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 126. TABLE 54 ASIA PACIFIC: ELISA REAGENTS & KITS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 126. TABLE 55 LATIN AMERICA: ELISA REAGENTS & KITS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 127. TABLE 56 RAPID TEST REAGENTS & KITS MARKET, BY REGION, 2024–2031 (USD MILLION) 128. TABLE 57 NORTH AMERICA: RAPID TEST REAGENTS & KITS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 128. TABLE 58 EUROPE: RAPID TEST REAGENTS & KITS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 129. TABLE 59 ASIA PACIFIC: RAPID TEST REAGENTS & KITS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 129. TABLE 60 LATIN AMERICA: RAPID TEST REAGENTS & KITS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 130. TABLE 61 CLIA REAGENTS & KITS MARKET, BY REGION, 2024–2031 (USD MILLION) 131. TABLE 62 NORTH AMERICA: CLIA REAGENTS & KITS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 131. TABLE 63 EUROPE: CLIA REAGENTS & KITS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 132. TABLE 64 ASIA PACIFIC: CLIA REAGENTS & KITS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 132. TABLE 65 LATIN AMERICA: CLIA REAGENTS & KITS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 133. TABLE 66 IFA REAGENTS & KITS MARKET, BY REGION, 2024–2031 (USD MILLION) 133. TABLE 67 NORTH AMERICA: IFA REAGENTS & KITS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 134. TABLE 68 EUROPE: IFA REAGENTS & KITS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 134. TABLE 69 ASIA PACIFIC: IFA REAGENTS & KITS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 135. TABLE 70 LATIN AMERICA: IFA REAGENTS & KITS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 135. TABLE 71 WESTERN BLOT REAGENTS & KITS MARKET, BY REGION,. 2024–2031 (USD MILLION) 136. TABLE 72 NORTH AMERICA: WESTERN BLOT REAGENTS & KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 137. TABLE 73 EUROPE: WESTERN BLOT REAGENTS & KITS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 137. TABLE 74 ASIA PACIFIC: WESTERN BLOT REAGENTS & KITS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 138. TABLE 75 LATIN AMERICA: WESTERN BLOT REAGENTS & KITS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 138. TABLE 76 OTHER REAGENTS & KITS MARKET, BY REGION, 2024–2031 (USD MILLION) 139. TABLE 77 NORTH AMERICA: OTHER REAGENTS & KITS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 139. TABLE 78 EUROPE: OTHER REAGENTS & KITS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 140. TABLE 79 ASIA PACIFIC: OTHER REAGENTS & KITS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 140. TABLE 80 LATIN AMERICA: OTHER REAGENTS & KITS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 141. TABLE 81 KEY ANALYZERS AVAILABLE IN MARKET 142. TABLE 82 IMMUNOASSAY ANALYZERS MARKET, BY REGION, 2024–2031 (USD MILLION) 143. TABLE 83 NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 143. TABLE 84 EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 144. TABLE 85 ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 144. TABLE 86 LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 145. TABLE 87 IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 146. TABLE 88 OPEN-ENDED IMMUNOASSAY SYSTEMS MARKET, BY REGION,. 2024–2031 (USD MILLION) 146. TABLE 89 NORTH AMERICA: OPEN-ENDED IMMUNOASSAY SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 147. TABLE 90 EUROPE: OPEN-ENDED IMMUNOASSAY SYSTEMS MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 147. TABLE 91 ASIA PACIFIC: OPEN-ENDED IMMUNOASSAY SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 148. TABLE 92 LATIN AMERICA: OPEN-ENDED IMMUNOASSAY SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 148. TABLE 93 CLOSED-ENDED IMMUNOASSAY SYSTEMS MARKET, BY REGION,. 2024–2031 (USD MILLION) 149. TABLE 94 NORTH AMERICA: CLOSED-ENDED IMMUNOASSAY SYSTEMS MARKET,. BY COUNTRY, 2024–2031 (USD MILLION) 149. TABLE 95 EUROPE: CLOSED-ENDED IMMUNOASSAY SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 150. TABLE 96 ASIA PACIFIC: CLOSED-ENDED IMMUNOASSAY SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 150. TABLE 97 LATIN AMERICA: CLOSED-ENDED IMMUNOASSAY SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 151. TABLE 98 IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,. 2024–2031 (USD MILLION) 151. TABLE 99 IMMUNOASSAY ANALYZERS MARKET FOR RENTAL PURCHASE, BY REGION,. 2024–2031 (USD MILLION) 152. TABLE 100 NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET FOR RENTAL PURCHASE, BY COUNTRY, 2024–2031 (USD MILLION) 153. TABLE 101 EUROPE: IMMUNOASSAY ANALYZERS MARKET FOR RENTAL PURCHASE,. BY COUNTRY, 2024–2031 (USD MILLION) 153. TABLE 102 ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET FOR RENTAL PURCHASE,. BY COUNTRY, 2024–2031 (USD MILLION) 154. TABLE 103 LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET FOR RENTAL PURCHASE,. BY COUNTRY, 2024–2031 (USD MILLION) 154. TABLE 104 IMMUNOASSAY ANALYZERS MARKET FOR OUTRIGHT PURCHASE, BY REGION, 2024–2031 (USD MILLION) 155. TABLE 105 NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET FOR OUTRIGHT PURCHASE, BY COUNTRY, 2024–2031 (USD MILLION) 155. TABLE 106 EUROPE: IMMUNOASSAY ANALYZERS MARKET FOR OUTRIGHT PURCHASE,. BY COUNTRY, 2024–2031 (USD MILLION) 156. TABLE 107 ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET FOR OUTRIGHT PURCHASE,. BY COUNTRY, 2024–2031 (USD MILLION) 156. TABLE 108 LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET FOR OUTRIGHT PURCHASE, BY COUNTRY, 2024–2031 (USD MILLION) 157. TABLE 109 IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 159. TABLE 110 KEY ELISA TECHNOLOGIES AVAILABLE IN MARKET 160. TABLE 111 IMMUNOASSAY MARKET FOR ELISA, BY REGION, 2024–2031 (USD MILLION) 161. TABLE 112 NORTH AMERICA: IMMUNOASSAY MARKET FOR ELISA, BY COUNTRY,. 2024–2031 (USD MILLION) 161. TABLE 113 EUROPE: IMMUNOASSAY MARKET FOR ELISA, BY COUNTRY,. 2024–2031 (USD MILLION) 162. TABLE 114 ASIA PACIFIC: IMMUNOASSAY MARKET FOR ELISA, BY COUNTRY,. 2024–2031 (USD MILLION) 162. TABLE 115 LATIN AMERICA: IMMUNOASSAY MARKET FOR ELISA, BY COUNTRY,. 2024–2031 (USD MILLION) 163. TABLE 116 IMMUNOASSAY MARKET FOR CLIA, BY REGION, 2024–2031 (USD MILLION) 164. TABLE 117 NORTH AMERICA: IMMUNOASSAY MARKET FOR CLIA, BY COUNTRY,. 2024–2031 (USD MILLION) 164. TABLE 118 EUROPE: IMMUNOASSAY MARKET FOR CLIA, BY COUNTRY,. 2024–2031 (USD MILLION) 165. TABLE 119 ASIA PACIFIC: IMMUNOASSAY MARKET FOR CLIA, BY COUNTRY,. 2024–2031 (USD MILLION) 165. TABLE 120 LATIN AMERICA: IMMUNOASSAY MARKET FOR CLIA, BY COUNTRY,. 2024–2031 (USD MILLION) 166. TABLE 121 IMMUNOASSAY MARKET FOR IFA, BY REGION, 2024–2031 (USD MILLION) 167. TABLE 122 NORTH AMERICA: IMMUNOASSAY MARKET FOR IFA, BY COUNTRY,. 2024–2031 (USD MILLION) 167. TABLE 123 EUROPE: IMMUNOASSAY MARKET FOR IFA, BY COUNTRY,. 2024–2031 (USD MILLION) 168. TABLE 124 ASIA PACIFIC: IMMUNOASSAY MARKET FOR IFA, BY COUNTRY,. 2024–2031 (USD MILLION) 168. TABLE 125 LATIN AMERICA: IMMUNOASSAY MARKET FOR IFA, BY COUNTRY,. 2024–2031 (USD MILLION) 169. TABLE 126 KEY RAPID TESTS AVAILABLE IN MARKET 169. TABLE 127 IMMUNOASSAY MARKET FOR RAPID TESTS, BY REGION,. 2024–2031 (USD MILLION) 170. TABLE 128 NORTH AMERICA: IMMUNOASSAY MARKET FOR RAPID TESTS, BY COUNTRY, 2024–2031 (USD MILLION) 170. TABLE 129 EUROPE: IMMUNOASSAY MARKET FOR RAPID TESTS, BY COUNTRY,. 2024–2031 (USD MILLION) 171. TABLE 130 ASIA PACIFIC: IMMUNOASSAY MARKET FOR RAPID TESTS, BY COUNTRY,. 2024–2031 (USD MILLION) 171. TABLE 131 LATIN AMERICA: IMMUNOASSAY MARKET FOR RAPID TESTS, BY COUNTRY,. 2024–2031 (USD MILLION) 172. TABLE 132 KEY WESTERN BLOTTING SYSTEMS AVAILABLE IN MARKET 172. TABLE 133 IMMUNOASSAY MARKET FOR WESTERN BLOTTING, BY REGION,. 2024–2031 (USD MILLION) 173. TABLE 134 NORTH AMERICA: IMMUNOASSAY MARKET FOR WESTERN BLOTTING,. BY COUNTRY, 2024–2031 (USD MILLION) 173. TABLE 135 EUROPE: IMMUNOASSAY MARKET FOR WESTERN BLOTTING, BY COUNTRY,. 2024–2031 (USD MILLION) 174. TABLE 136 ASIA PACIFIC: IMMUNOASSAY MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2024–2031 (USD MILLION) 174. TABLE 137 LATIN AMERICA: IMMUNOASSAY MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2024–2031 (USD MILLION) 175. TABLE 138 IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES, BY REGION,. 2024–2031 (USD MILLION) 176. TABLE 139 NORTH AMERICA: IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES,. BY COUNTRY, 2024–2031 (USD MILLION) 176. TABLE 140 EUROPE: IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 177. TABLE 141 ASIA PACIFIC: IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES,. BY COUNTRY, 2024–2031 (USD MILLION) 177. TABLE 142 LATIN AMERICA: IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES,. BY COUNTRY, 2024–2031 (USD MILLION) 178. TABLE 143 IMMUNOASSAY MARKET, BY SPECIMEN, 2024–2031 (USD MILLION) 180. TABLE 144 IMMUNOASSAY MARKET FOR BLOOD SPECIMENS, BY REGION,. 2024–2031 (USD MILLION) 181. TABLE 145 NORTH AMERICA: IMMUNOASSAY MARKET FOR BLOOD SPECIMENS, BY COUNTRY, 2024–2031 (USD MILLION) 182. TABLE 146 EUROPE: IMMUNOASSAY MARKET FOR BLOOD SPECIMENS, BY COUNTRY,. 2024–2031 (USD MILLION) 182. TABLE 147 ASIA PACIFIC: IMMUNOASSAY MARKET FOR BLOOD SPECIMENS, BY COUNTRY, 2024–2031 (USD MILLION) 183. TABLE 148 LATIN AMERICA: IMMUNOASSAY MARKET FOR BLOOD SPECIMENS, BY COUNTRY, 2024–2031 (USD MILLION) 183. TABLE 149 IMMUNOASSAY MARKET FOR SALIVA SPECIMENS, BY REGION,. 2024–2031 (USD MILLION) 184. TABLE 150 NORTH AMERICA: IMMUNOASSAY MARKET FOR SALIVA SPECIMENS, BY COUNTRY, 2024–2031 (USD MILLION) 185. TABLE 151 EUROPE: IMMUNOASSAY MARKET FOR SALIVA SPECIMENS, BY COUNTRY,. 2024–2031 (USD MILLION) 185. TABLE 152 ASIA PACIFIC: IMMUNOASSAY MARKET FOR SALIVA SPECIMENS, BY COUNTRY, 2024–2031 (USD MILLION) 186. TABLE 153 LATIN AMERICA: IMMUNOASSAY MARKET FOR SALIVA SPECIMENS, BY COUNTRY, 2024–2031 (USD MILLION) 186. TABLE 154 IMMUNOASSAY MARKET FOR URINE SPECIMENS, BY REGION,. 2024–2031 (USD MILLION) 187. TABLE 155 NORTH AMERICA: IMMUNOASSAY MARKET FOR URINE SPECIMENS, BY COUNTRY, 2024–2031 (USD MILLION) 188. TABLE 156 EUROPE: IMMUNOASSAY MARKET FOR URINE SPECIMENS, BY COUNTRY,. 2024–2031 (USD MILLION) 188. TABLE 157 ASIA PACIFIC: IMMUNOASSAY MARKET FOR URINE SPECIMENS, BY COUNTRY, 2024–2031 (USD MILLION) 189. TABLE 158 LATIN AMERICA: IMMUNOASSAY MARKET FOR URINE SPECIMENS, BY COUNTRY, 2024–2031 (USD MILLION) 189. TABLE 159 IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY REGION,. 2024–2031 (USD MILLION) 190. TABLE 160 NORTH AMERICA: IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2024–2031 (USD MILLION) 191. TABLE 161 EUROPE: IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY COUNTRY,. 2024–2031 (USD MILLION) 191. TABLE 162 ASIA PACIFIC: IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2024–2031 (USD MILLION) 192. TABLE 163 LATIN AMERICA: IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2024–2031 (USD MILLION) 192. TABLE 164 IMMUNOASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 194. TABLE 165 IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2024–2031 (USD MILLION) 195. TABLE 166 NORTH AMERICA: IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES,. BY COUNTRY, 2024–2031 (USD MILLION) 196. TABLE 167 EUROPE: IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 196. TABLE 168 ASIA PACIFIC: IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 197. TABLE 169 LATIN AMERICA: IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES,. BY COUNTRY, 2024–2031 (USD MILLION) 197. TABLE 170 IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY REGION,. 2024–2031 (USD MILLION) 198. TABLE 171 NORTH AMERICA: IMMUNOASSAY MARKET FOR ENDOCRINOLOGY,. BY COUNTRY, 2024–2031 (USD MILLION) 199. TABLE 172 EUROPE: IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY COUNTRY,. 2024–2031 (USD MILLION) 199. TABLE 173 ASIA PACIFIC: IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 200. TABLE 174 LATIN AMERICA: IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 200. TABLE 175 KEY PRODUCTS AVAILABLE FOR CARDIOLOGY APPLICATIONS 202. TABLE 176 IMMUNOASSAY MARKET FOR CARDIOLOGY, BY REGION,. 2024–2031 (USD MILLION) 202. TABLE 177 NORTH AMERICA: IMMUNOASSAY MARKET FOR CARDIOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 203. TABLE 178 EUROPE: IMMUNOASSAY MARKET FOR CARDIOLOGY, BY COUNTRY,. 2024–2031 (USD MILLION) 203. TABLE 179 ASIA PACIFIC: IMMUNOASSAY MARKET FOR CARDIOLOGY, BY COUNTRY,. 2024–2031 (USD MILLION) 204. TABLE 180 LATIN AMERICA: IMMUNOASSAY MARKET FOR CARDIOLOGY, BY COUNTRY,. 2024–2031 (USD MILLION) 204. TABLE 181 IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS, BY REGION,. 2024–2031 (USD MILLION) 205. TABLE 182 NORTH AMERICA: IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS,. BY COUNTRY, 2024–2031 (USD MILLION) 206. TABLE 183 EUROPE: IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 206. TABLE 184 ASIA PACIFIC: IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS,. BY COUNTRY, 2024–2031 (USD MILLION) 207. TABLE 185 LATIN AMERICA: IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS,. BY COUNTRY, 2024–2031 (USD MILLION) 207. TABLE 186 IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS, BY REGION,. 2024–2031 (USD MILLION) 208. TABLE 187 NORTH AMERICA: IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS,. BY COUNTRY, 2024–2031 (USD MILLION) 209. TABLE 188 EUROPE: IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION) 209. TABLE 189 ASIA PACIFIC: IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS,. BY COUNTRY, 2024–2031 (USD MILLION) 210. TABLE 190 LATIN AMERICA: IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS,. BY COUNTRY, 2024–2031 (USD MILLION) 210. TABLE 191 IMMUNOASSAY MARKET FOR ONCOLOGY, BY REGION, 2024–2031 (USD MILLION) 212. TABLE 192 NORTH AMERICA: IMMUNOASSAY MARKET FOR ONCOLOGY, BY COUNTRY,. 2024–2031 (USD MILLION) 212. TABLE 193 EUROPE: IMMUNOASSAY MARKET FOR ONCOLOGY, BY COUNTRY,. 2024–2031 (USD MILLION) 213. TABLE 194 ASIA PACIFIC: IMMUNOASSAY MARKET FOR ONCOLOGY, BY COUNTRY,. 2024–2031 (USD MILLION) 213. TABLE 195 LATIN AMERICA: IMMUNOASSAY MARKET FOR ONCOLOGY, BY COUNTRY,. 2024–2031 (USD MILLION) 214. TABLE 196 KEY PRODUCTS AVAILABLE FOR BONE & MINERAL DISORDERS 215. TABLE 197 IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS, BY REGION,. 2024–2031 (USD MILLION) 215. TABLE 198 NORTH AMERICA: IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS,. BY COUNTRY, 2024–2031 (USD MILLION) 216. TABLE 199 EUROPE: IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS,. BY COUNTRY, 2024–2031 (USD MILLION) 216. TABLE 200 ASIA PACIFIC: IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS,. BY COUNTRY, 2024–2031 (USD MILLION) 217. TABLE 201 LATIN AMERICA: IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS,. BY COUNTRY, 2024–2031 (USD MILLION) 217. TABLE 202 KEY PRODUCTS AVAILABLE FOR DRUG MONITORING & TESTING 218. TABLE 203 KEY IMMUNOASSAY PRODUCTS AVAILABLE FOR DRUG MONITORING & TESTING 219. TABLE 204 IMMUNOASSAY MARKET FOR DRUG MONITORING & TESTING, BY REGION,. 2024–2031 (USD MILLION) 219. TABLE 205 NORTH AMERICA: IMMUNOASSAY MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 219. TABLE 206 EUROPE: IMMUNOASSAY MARKET FOR DRUG MONITORING & TESTING,. BY COUNTRY, 2024–2031 (USD MILLION) 220. TABLE 207 ASIA PACIFIC: IMMUNOASSAY MARKET FOR DRUG MONITORING & TESTING,. BY COUNTRY, 2024–2031 (USD MILLION) 220. TABLE 208 LATIN AMERICA: IMMUNOASSAY MARKET FOR DRUG MONITORING & TESTING,. BY COUNTRY, 2024–2031 (USD MILLION) 221. TABLE 209 IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY REGION,. 2024–2031 (USD MILLION) 222. TABLE 210 NORTH AMERICA: IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY COUNTRY, 2024–2031 (USD MILLION) 222. TABLE 211 EUROPE: IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY COUNTRY,. 2024–2031 (USD MILLION) 223. TABLE 212 ASIA PACIFIC: IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY COUNTRY, 2024–2031 (USD MILLION) 223. TABLE 213 LATIN AMERICA: IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY COUNTRY, 2024–2031 (USD MILLION) 224. TABLE 214 KEY PRODUCTS AVAILABLE FOR NEWBORN SCREENING 224. TABLE 215 IMMUNOASSAY MARKET FOR NEWBORN SCREENING, BY REGION,. 2024–2031 (USD MILLION) 225. TABLE 216 NORTH AMERICA: IMMUNOASSAY MARKET FOR NEWBORN SCREENING,. BY COUNTRY, 2024–2031 (USD MILLION) 225. TABLE 217 EUROPE: IMMUNOASSAY MARKET FOR NEWBORN SCREENING, BY COUNTRY, 2024–2031 (USD MILLION) 226. TABLE 218 ASIA PACIFIC: IMMUNOASSAY MARKET FOR NEWBORN SCREENING, BY COUNTRY, 2024–2031 (USD MILLION) 226. TABLE 219 LATIN AMERICA: IMMUNOASSAY MARKET FOR NEWBORN SCREENING,. BY COUNTRY, 2024–2031 (USD MILLION) 227. TABLE 220 IMMUNOASSAY MARKET FOR OTHER APPLICATIONS, BY REGION,. 2024–2031 (USD MILLION) 228. TABLE 221 NORTH AMERICA: IMMUNOASSAY MARKET FOR OTHER APPLICATIONS,. BY COUNTRY, 2024–2031 (USD MILLION) 228. TABLE 222 EUROPE: IMMUNOASSAY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 229. TABLE 223 ASIA PACIFIC: IMMUNOASSAY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 229. TABLE 224 LATIN AMERICA: IMMUNOASSAY MARKET FOR OTHER APPLICATIONS,. BY COUNTRY, 2024–2031 (USD MILLION) 230. TABLE 225 IMMUNOASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 232. TABLE 226 IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS, BY REGION,. 2024–2031 (USD MILLION) 233. TABLE 227 NORTH AMERICA: IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS,. BY COUNTRY, 2024–2031 (USD MILLION) 234. TABLE 228 EUROPE: IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2024–2031 (USD MILLION) 234. TABLE 229 ASIA PACIFIC: IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS,. BY COUNTRY, 2024–2031 (USD MILLION) 235. TABLE 230 LATIN AMERICA: IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS,. BY COUNTRY, 2024–2031 (USD MILLION) 235. TABLE 231 IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY REGION,. 2024–2031 (USD MILLION) 237. TABLE 232 NORTH AMERICA: IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES,. BY COUNTRY, 2024–2031 (USD MILLION) 237. TABLE 233 EUROPE: IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 238. TABLE 234 ASIA PACIFIC: IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES,. BY COUNTRY, 2024–2031 (USD MILLION) 238. TABLE 235 LATIN AMERICA: IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES,. BY COUNTRY, 2024–2031 (USD MILLION) 239. TABLE 236 IMMUNOASSAY MARKET FOR HOME CARE SETTINGS, BY REGION,. 2024–2031 (USD MILLION) 240. TABLE 237 NORTH AMERICA: IMMUNOASSAY MARKET FOR HOME CARE SETTINGS,. BY COUNTRY, 2024–2031 (USD MILLION) 240. TABLE 238 EUROPE: IMMUNOASSAY MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2024–2031 (USD MILLION) 241. TABLE 239 ASIA PACIFIC: IMMUNOASSAY MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2024–2031 (USD MILLION) 241. TABLE 240 LATIN AMERICA: IMMUNOASSAY MARKET FOR HOME CARE SETTINGS,. BY COUNTRY, 2024–2031 (USD MILLION) 242. TABLE 241 IMMUNOASSAY MARKET FOR BLOOD BANKS, BY REGION,. 2024–2031 (USD MILLION) 243. TABLE 242 NORTH AMERICA: IMMUNOASSAY MARKET FOR BLOOD BANKS, BY COUNTRY, 2024–2031 (USD MILLION) 243. TABLE 243 EUROPE: IMMUNOASSAY MARKET FOR BLOOD BANKS, BY COUNTRY,. 2024–2031 (USD MILLION) 244. TABLE 244 ASIA PACIFIC: IMMUNOASSAY MARKET FOR BLOOD BANKS, BY COUNTRY,. 2024–2031 (USD MILLION) 244. TABLE 245 LATIN AMERICA: IMMUNOASSAY MARKET FOR BLOOD BANKS, BY COUNTRY, 2024–2031 (USD MILLION) 245. TABLE 246 IMMUNOASSAY MARKET, BY REGION, 2024–2031 (USD MILLION) 247. TABLE 247 NORTH AMERICA: IMMUNOASSAY MARKET, BY COUNTRY,. 2024–2031 (USD MILLION) 249. TABLE 248 NORTH AMERICA: IMMUNOASSAY MARKET, BY PRODUCT,. 2024–2031 (USD MILLION) 249. TABLE 249 NORTH AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,. 2024–2031 (USD MILLION) 250. TABLE 250 NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE,. 2024–2031 (USD MILLION) 250. TABLE 251 NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2024–2031 (USD MILLION) 251. TABLE 252 NORTH AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY,. 2024–2031 (USD MILLION) 251. TABLE 253 NORTH AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN,. 2024–2031 (USD MILLION) 252. TABLE 254 NORTH AMERICA: IMMUNOASSAY MARKET, BY APPLICATION,. 2024–2031 (USD MILLION) 252. TABLE 255 NORTH AMERICA: IMMUNOASSAY MARKET, BY END USER,. 2024–2031 (USD MILLION) 253. TABLE 256 US: NUMBER OF IN VITRO DIAGNOSTIC TESTS CONDUCTED,. 2022–2031 (BILLION UNITS) 254. TABLE 257 US: IMMUNOASSAY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 255. TABLE 258 US: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,. 2024–2031 (USD MILLION) 255. TABLE 259 US: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 256. TABLE 260 US: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,. 2024–2031 (USD MILLION) 256. TABLE 261 US: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 257. TABLE 262 US: IMMUNOASSAY MARKET, BY SPECIMEN, 2024–2031 (USD MILLION) 257. TABLE 263 US: IMMUNOASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 258. TABLE 264 US: IMMUNOASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 258. TABLE 265 CANADA: ESTIMATED PREVALENCE OF DIABETES, 2025 VS. 2034 259. TABLE 266 CANADA: IMMUNOASSAY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 260. TABLE 267 CANADA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,. 2024–2031 (USD MILLION) 260. TABLE 268 CANADA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE,. 2024–2031 (USD MILLION) 261. TABLE 269 CANADA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,. 2024–2031 (USD MILLION) 261. TABLE 270 CANADA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 262. TABLE 271 CANADA: IMMUNOASSAY MARKET, BY SPECIMEN, 2024–2031 (USD MILLION) 262. TABLE 272 CANADA: IMMUNOASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 263. TABLE 273 CANADA: IMMUNOASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 263. TABLE 274 EUROPE: IMMUNOASSAY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 264. TABLE 275 EUROPE: IMMUNOASSAY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 265. TABLE 276 EUROPE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,. 2024–2031 (USD MILLION) 265. TABLE 277 EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE,. 2024–2031 (USD MILLION) 266. TABLE 278 EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,. 2024–2031 (USD MILLION) 266. TABLE 279 EUROPE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 267. TABLE 280 EUROPE: IMMUNOASSAY MARKET, BY SPECIMEN, 2024–2031 (USD MILLION) 267. TABLE 281 EUROPE: IMMUNOASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 268. TABLE 282 EUROPE: IMMUNOASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 268. TABLE 283 GERMANY: IMMUNOASSAY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 269. TABLE 284 GERMANY: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,. 2024–2031 (USD MILLION) 270. TABLE 285 GERMANY: IMMUNOASSAY ANALYZERS MARKET, BY TYPE,. 2024–2031 (USD MILLION) 270. TABLE 286 GERMANY: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,. 2024–2031 (USD MILLION) 271. TABLE 287 GERMANY: IMMUNOASSAY MARKET, BY TECHNOLOGY,. 2024–2031 (USD MILLION) 271. TABLE 288 GERMANY: IMMUNOASSAY MARKET, BY SPECIMEN, 2024–2031 (USD MILLION) 272. TABLE 289 GERMANY: IMMUNOASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 272. TABLE 290 GERMANY: IMMUNOASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 273. TABLE 291 ITALY: IMMUNOASSAY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 274. TABLE 292 ITALY: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,. 2024–2031 (USD MILLION) 274. TABLE 293 ITALY: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 275. TABLE 294 ITALY: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,. 2024–2031 (USD MILLION) 275. TABLE 295 ITALY: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 276. TABLE 296 ITALY: IMMUNOASSAY MARKET, BY SPECIMEN, 2024–2031 (USD MILLION) 276. TABLE 297 ITALY: IMMUNOASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 277. TABLE 298 ITALY: IMMUNOASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 277. TABLE 299 FRANCE: IMMUNOASSAY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 278. TABLE 300 FRANCE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,. 2024–2031 (USD MILLION) 279. TABLE 301 FRANCE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE,. 2024–2031 (USD MILLION) 279. TABLE 302 FRANCE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,. 2024–2031 (USD MILLION) 280. TABLE 303 FRANCE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 280. TABLE 304 FRANCE: IMMUNOASSAY MARKET, BY SPECIMEN, 2024–2031 (USD MILLION) 281. TABLE 305 FRANCE: IMMUNOASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 281. TABLE 306 FRANCE: IMMUNOASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 282. TABLE 307 UK: IMMUNOASSAY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 283. TABLE 308 UK: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,. 2024–2031 (USD MILLION) 284.
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医療機器)の最新刊レポート
MarketsandMarkets社の Medical Devices分野 での最新刊レポート
本レポートと同じKEY WORD(immunoassay)の最新刊レポート
よくあるご質問MarketsandMarkets社はどのような調査会社ですか?マーケッツアンドマーケッツ(MarketsandMarkets)は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
|